GID.AX - GI Dynamics, Inc.

ASX - ASX Delayed Price. Currency in AUD
0.02
+0.00 (+5.26%)
At close: 10:04AM AEDT
Stock chart is not supported by your current browser
Previous close0.02
Open0.02
Bid0.02 x 0
Ask0.02 x 0
Day's range0.02 - 0.02
52-week range0.02 - 0.04
Volume86,246
Avg. volume67,525
Market cap15.333M
Beta (3Y monthly)3.31
PE ratio (TTM)N/A
EPS (TTM)-0.01
Earnings date13 Aug 2018 - 17 Aug 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.03
  • GI Dynamics Announces Results of Special Meeting
    Business Wire7 days ago

    GI Dynamics Announces Results of Special Meeting

    GI Dynamics, Inc. (GID.AX), a medical device company that is developing EndoBarrier, held a Special Meeting on Monday, 29 October 2018 at 5:00pm United States Eastern Daylight Time (being Tuesday, 30 October 2018 at 8:00am Australian Eastern Daylight Time) and is pleased to announce that each of the resolutions put to stockholders as set forth in the Proxy Statement dated 15 October 2018 (Proxy Statement), were passed. As specified in the Proxy Statement, the Company notes that the CDIs to be issued to Crystal Amber Fund Limited (or its nominee) and certain sophisticated and professional investors in Australia and the United States under the second tranche of the Placement will be issued after receipt of all second tranche funds and will rank equally in all respects with CDIs on issue at the date of allotment.

  • Business Wirelast month

    GI Dynamics Announces Selection of New Notified Body

    GI Dynamics, Inc. (GID.AX), a medical device company that is developing EndoBarrier for patients with type 2 diabetes and obesity, is pleased to announce the selection of Intertek as the company’s notified body to continue working toward attaining the EndoBarrier CE Mark. GI Dynamics selected Intertek for its medical device expertise and availability to support the clinical and regulatory requirements of EndoBarrier and GI Dynamics.

  • Business Wire2 months ago

    GI Dynamics Announces AUD $6.9m Private Placement to be Completed in Two Tranches

    GI Dynamics, Inc. (GID.AX), a medical device company that is developing EndoBarrier for patients diagnosed with type 2 diabetes and obesity, is pleased to announce it has received binding commitments for a private placement of 347,222,250 CHESS Depositary Interests (CDIs) of the Company (representing 6,944,445 shares of common stock) at an issue price of AUD $0.020 per CDI to certain sophisticated and professional investors in Australia, the United States, and the United Kingdom to raise approximately AUD $6.944 million (representing approximately USD $5 million using an exchange rate of USD $0.72 per AUD) (Placement). The issue of CDIs under the Placement will occur in two tranches.

  • Business Wire3 months ago

    GI Dynamics Announces FDA Approval for EndoBarrier Pivotal Trial

    GI Dynamics Inc. (GID.AX), a medical device company that is developing EndoBarrier for patients diagnosed with type 2 diabetes and obesity, is pleased to announce it has received approval of an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin enrollment in a pivotal trial evaluating the safety and efficacy of EndoBarrier in the United States pending Institutional Review Board (IRB) approval.

  • Who Are The Largest Shareholders In GI Dynamics Inc (ASX:GID)?
    Simply Wall St.5 months ago

    Who Are The Largest Shareholders In GI Dynamics Inc (ASX:GID)?

    In this analysis, my focus will be on developing a perspective on GI Dynamics Inc’s (ASX:GID) latest ownership structure, a less discussed, but important factor. Ownership structure has been foundRead More...

  • Business Wire6 months ago

    EndoBarrier Meta-Analysis Published in Diabetes Care Journal

    GI Dynamics® Inc. , a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the meta-analysis, “Effects of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Type 2 Diabetic Patients with Obesity: A Meta-analysis with Secondary Analysis on Weight Loss and Hormonal Changes,” by Pichamol Jirapinyo, MD, of Brigham and Women’s ...

  • Business Wire10 months ago

    GI Dynamics Announces AUD $2.05m Private Placement and Close of First Tranche of AUD ~$1m

    GI Dynamics®, Inc. , a medical device company that is developing EndoBarrier® is pleased to announce that it has received binding commitments for a private placement of 58,780,619 CHESS Depositary Interests of the Company at an issue price of AUD $0.035 per CDI to sophisticated and professional investors in Australia, the United States, and the United Kingdom to raise approximately AUD $2.05 million ...

  • Business Wire10 months ago

    GI Dynamics, Inc. Provides 2017 Review and 2018 Business Outlook

    GI Dynamics®, Inc. , a medical device company that is developing EndoBarrier® provides shareholders with a review of 2017 activities and its 2018 business outlook.

  • Business Wirelast year

    GI Dynamics Announces Change to Board of Directors

    GI Dynamics®, Inc. , a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America, announces today that the board of directors has received the resignation of GI Dynamics non-executive directors Anne Keating and Graham Bradley.

  • Business Wirelast year

    GI Dynamics to Provide Corporate Update and 2017 Third Quarter Results

    GI Dynamics® Inc. , a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announces it will provide a corporate update and discuss 2017 third quarter results to investors.

  • Business Wirelast year

    GI Dynamics Receives CE Certificate of Conformity Withdrawal Notice for EndoBarrier

    GI Dynamics®, Inc. , a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America has received notification from its notified body SGS United Kingdom, Limited that SGS will withdraw the CE Certificate of Conformity for EndoBarrier effective 12 November 2017.